Avastin – breast cancer drug, fails to pass the FDA advisory panel vote on efficacy
According to a Food and Drug Administration (FDA) advisory committee’s (The Oncology Drugs Advisory Committee, or ODAC) recommendation this Tuesday, the marketing approval of the popular breast cancer drug, Avastin or Bevacizumab should be withdrawn.
Linear Mode
